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There are limited data on the downstream effects of hepatocellular carcinoma (HCC) surveillance, including the frequency of 
false-positive results. We aimed to quantify the incidence of indeterminate nodules (INs) and the follow-up testing needed to 
resolve these findings among patients enrolled in a structured HCC surveillance program. We retrospectively analyzed adult 
patients with cirrhosis enrolled in a structured HCC surveillance program in a large tertiary care center. Outcomes included 
surveillance benefits, defined as early HCC detection, and harm, defined as INs prompting additional diagnostic evaluation. 
Among 999 patients followed for a median of 2.2 years, HCC surveillance imaging was consistently completed every 6, 9, and 
12 months in 46%, 51%, and 68% of patients, respectively. Of 256 (25.6%) patients with abnormal imaging, 69 (27.0%) were 
diagnosed with HCC and 187 (73.0%) with INs. Most HCC (n = 54, 78.3%) were found within Milan criteria. Among those 
with an IN, 78.1% returned to ultrasound surveillance after a median of 2 (interquartile range [IQR], 1-3) negative computed 
tomography (CT)/magnetic resonance imaging (MRI) scans, and 21.9% continued CT/MRI imaging (median, 1; IQR, 1-2). 
Eleven patients underwent diagnostic liver biopsy. Hypoalbuminemia, thrombocytopenia, and larger nodule size were inde-
pendently associated with HCC diagnosis. In conclusion, 1 in 4 patients enrolled in an HCC surveillance program had abnor-
mal surveillance imaging, but three-fourths of the lesions were INs, resulting in downstream harm. Improved risk-stratification 
tools are needed to identify nodules that are benign to reduce follow-up diagnostic evaluation.
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Hepatocellular carcinoma (HCC) is the sixth most 
common cancer and the third leading cause of can-
cer-related death worldwide.(1,2) In the United States, 
the annual incidence and mortality of HCC are 
increasing, largely because of a peak in hepatitis C 
virus (HCV)–related complications and the emer-
gence of nonalcoholic fatty liver disease (NAFLD) 
as a rapidly growing cause of chronic liver disease.(3) 
This high HCC-related mortality is due to a sig-
nificant proportion of patients presenting with late-
stage tumors, which only have palliative treatment 
options.(4,5) Accordingly, several professional society 
guidelines recommend HCC surveillance using ultra-
sound (US) ± alpha-fetoprotein (AFP) in patients with 
cirrhosis to improve early tumor detection and curative 
treatment receipt.(6-8)
The value of a cancer-screening program must 
weigh any benefits against potential harm of the 
screening tests. The benefit of HCC surveillance is 
dependent on adherence to the surveillance program 
and its effectiveness.(9) Prior studies suggest that 
adherence to HCC surveillance in real-world clinical 
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practice is low at 15%-20% for 1-time screening and 
5%-10% for biannual surveillance, highlighting a 
need for interventions to increase surveillance utiliza-
tion.(10-13) Similarly, studies have suggested variability 
in sensitivity to detect HCC at an early stage with high 
rates of surveillance failure even in high-volume aca-
demic centers.(14) Conversely, finding nodules during 
US surveillance that do not have the characteristic fea-
tures of HCC on multiphasic computed tomography 
(CT) or magnetic resonance imaging (MRI) nor typi-
cal features of benign lesions, ie, indeterminate nodules 
(INs), can result in physical harm (eg, radiation expo-
sure, contrast nephropathy, and biopsy complications), 
financial harm (eg, copays or lost wages), and/or psy-
chological harm (eg, worries about cancer), particularly 
if the nature of these nodules cannot be resolved after 
initial cross-sectional imaging.(15-17) Excess diagnostic 
testing is well established as a physical harm in patients 
undergoing colon, breast, and prostate cancer screen-
ing. However, this has been underexplored in patients 
undergoing HCC surveillance.(18-20) A randomized 
trial comparing 3- and 6-month surveillance using US 
found that 70% of focal lesions that were detected on 
US were not HCC. However, the downstream harm 
to those patients with INs was not characterized.(21) 
Similarly, a recent study from a safety-net hospital 
suggested that up to 27.5% of patients may experience 
physical harm related to false-positive findings. 
However, data in other practice settings are limited.(22)
The aims of this study were to determine the 
following:
1. The incidence of abnormal imaging results in 
a large cohort of cirrhosis patients enrolled in 
a structured HCC surveillance program at a 
high-volume academic liver center.
2. The frequency in which the nodule(s) detected on 
US were indeterminate and the number of cross-
sectional imaging scans needed to resolve the be-
nign versus malignant nature of these nodules.
3. The factors predictive of HCC among patients 
with abnormal imaging.
Patients and Methods
patient pOpUlatiOn anD Hcc 
sUrveillance prOgram
All adult patients (age ≥18 years) with cirrho-
sis followed in outpatient hepatology clinics at the 
University of Michigan between January 2010 and 
December 2015 were prospectively enrolled in a 
chronic disease management program. Enrollment 
in this program was previously shown to increase 
1-time screening after implementation.(23) The diag-
nosis of cirrhosis for entry into the chronic disease 
management program was based clinically on his-
tology, transient elastography, or imaging showing a 
nodular liver with or without associated signs of por-
tal hypertension. The chronic disease management 
program included serial tracking of all laboratory and 
imaging results, including HCC surveillance, with a 
capacity to generate reminders at designated inter-
vals. Clinic nurses contacted patients to complete 
any necessary surveillance testing at recommended 
intervals. According to the American Association for 
the Study of Liver Diseases (AASLD) guideline rec-
ommendations during the study period, abdominal 
imaging was required for completion of HCC sur-
veillance, whereas AFP testing was optional and its 
measurement was provider dependent, although 94% 
of patients in the cohort had at least 1 AFP mea-
surement.(8) The program captured outside imaging 
if results were scanned into the electronic medical 
record and patients were logged into the reminder 
system. Abdominal imaging done for nonsurveil-
lance purposes was also logged, given this satisfies 
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the need for surveillance testing. For this study, in-
cluded patients were required to have had at least 1 
surveillance US without IN or HCC at baseline. We 
excluded patients with a history of liver transplan-
tation and those who exclusively received MRI/CT–
based surveillance. Given that our aim was to quantify 
incidents of HCC and INs, we also excluded patients 
who had any history of HCC or any INs at base-
line. Abnormal imaging was defined as any imaging 
with a nodule that required follow-up multiphasic 
cross-sectional imaging. An IN was defined as any solid 
 lesion >1 cm in diameter that could not be categorized 
as definitely benign (ie, cyst or hemangioma) and did 
not meet diagnostic criteria for HCC on cross-sectional 
imaging. The recently adopted Liver Imaging Reporting 
and Data System (LI-RADS) imaging criteria were 
not available during the study period. However, most 
of the INs in this study would likely be classified as 
LI-RADS3 or LI-RADS4 lesions.
Data cOllectiOn anD 
DeFinitiOn OF OUtcOmes
Baseline demographics (age, sex, race, and ethnicity), 
etiology of cirrhosis, body mass index (BMI), and 
laboratory values (aspartate aminotransferase [AST], 
alanine aminotransferase [ALT], alkaline phospha-
tase, albumin, total bilirubin, AFP, creatinine, inter-
national normalized ratio [INR], and platelet count) 
at the time of enrollment were abstracted from elec-
tronic medical records. Complete records were avail-
able for all reviewed patients. Dates and results of all 
liver imaging (US and multiphasic contrast-enhanced 
CT or MRI) during the study period were recorded. 
For each  imaging study, the presence of any suspicious 
lesions was documented, and the number and size of 
the lesions were recorded when available. For CT/
MRI, diagnostic characteristics for HCC as defined 
by AASLD guidelines were noted, including arterial 
enhancement and delayed washout.(24) A small pro-
portion of patients (n = 6) were treated for HCC based 
on liver tumor board review and recommendations, 
 despite not meeting all imaging criteria for HCC. Data 
were collected from enrollment in the surveillance 
program until the end of the study  period (December 
2015), last outpatient clinic visit, or  development of 
HCC.
To evaluate the effectiveness of the surveillance 
program, we measured the proportion of patients who 
underwent imaging at 6-, 9-, and 12-month intervals.
statistical analYsis
The primary outcome of interest was surveillance 
harm, defined as the proportion of patients with INs 
who underwent subsequent follow-up testing (eg, 
4-phase CT, contrast-enhanced MRI, or biopsy).(16,25) 
Diagnostic testing for INs was defined as physical 
harm consistent with the definition adopted in the 
screening literature for other malignancies (eg, breast 
cancer(26) and prostate cancer(27)). We further strati-
fied patients by mild harm (1-3 multiphasic cross- 
sectional imaging tests without a diagnosis of HCC) 
and severe harm (≥4 multiphasic cross-sectional imag-
ing tests without a diagnosis of HCC or performance 
of a liver biopsy).
We also measured the surveillance benefits, 
defined as early-stage HCC detection. Early-stage 
HCC was defined as being within Milan criteria, the 
most common criteria for liver transplantation in the 
United States. Bivariate analyses were performed to 
assess frequencies of INs and HCC and patient-level 
factors associated with each outcome. Chi-square 
tests and Fisher’s exact tests were used for categor-
ical variables, and t tests were used for continuous 
variables. Variables with distributions that deviated 
from normality were reported by median and inter-
quartile range (IQR) rather than by conventional 
mean ± standard deviation and were compared 
using the Kruskal-Wallis test. A multivariate analy-
sis was conducted to identify factors associated with 
HCC and INs in the entire cohort. We used pre-
specified cutoffs for continuous variables, including 
platelet count, albumin, and nodule size. An addi-
tional multivariate analysis was conducted for cor-
relates of HCC in patients with abnormal imaging. 
We included variables from the univariate analysis 
(ie, baseline characteristics) with P values <0.1 in 
our multivariate analyses, for which P values <0.05 
were considered statistically significant. All analyses 
were performed in STATA, version 14 (StataCorp, 
College Station, TX). This study was approved 




A total of 999 patients met inclusion criteria (Table 1). 
The cohort consisted primarily of middle-aged (median 
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age, 58 years; IQR, 52.2-64.7 years), white (90.7%) 
individuals. Sex was evenly distributed (53.6% males), 
and the majority were overweight or obese (median 
baseline BMI, 29 kg/m2; IQR, 25-35 kg/m2). The 
etiology of cirrhosis was diverse (HCV, 35.6%; alco-
hol, 17.5%; NAFLD, 16.5%), and the median baseline 
Model for End-Stage Liver Disease (MELD) score 
was 7 (IQR, 6-10).
receipt OF Hcc sUrveillance
During the study period (median follow-up, 2.2 years; 
IQR, 0.9-3.9 years), HCC surveillance imaging was 
consistently completed every 6, 9, and 12 months in 
46%, 51%, and 68% of patients, respectively. Of the 
patients who did not complete surveillance every 6 
months, nearly half (44%) only missed 1 surveillance 
taBle 1. Baseline characteristics of patients With or Without abnormal imaging
Overall (n = 999)
Normal Imaging  
(No IN or HCC; n = 743)
Abnormal Imaging  
(IN or HCC; n = 256) P Value
Baseline clinical characteristics
Age, years 58.0 (52.2-64.7) 57.9 (51.8-64.5) 58.7 (52.7-65.2) 0.32
Sex, male 535 (53.6) 383 (51.5) 152 (59.4) 0.03
Race 0.32
White 849 (85.0) 630 (84.7) 219 (85.5)
Black 42 (4.2) 30 (4.0) 12 (4.7)
Asian 29 (2.9) 19 (2.6) 10 (3.9)
Hispanic/Latino (n = 974) 24 (2.5) 16 (2.2) 8 (3.1) 0.41
Etiology of cirrhosis 0.01
HCV 356 (35.6) 248 (33.4) 108 (42.2)
Alcoholic cirrhosis 175 (17.5) 143 (19.2) 32 (12.5)
NASH/NAFLD* 165 (16.5) 124 (16.7) 41 (16.0)
PBC/PSC 73 (7.3) 60 (8.1) 13 (5.1)
HBV 47 (4.7) 30 (4.0) 17 (6.6)
Other 182 (18.2) 137 (18.4) 45 (17.6)
BMI, kg/m2 29 (25-35) 29 (25-35) 29 (25-35) 0.84
Follow-up duration, years 2.2 (0.9-3.9) 1.9 (0.8-3.7) 2.9 (1.4-4.0) <0.001
Baseline laboratory values
MELD 7 (6-10) 6 (6-10) 7 (7-10) 0.24
Platelet count, K/µL 104 (74-147) 108.5 (75-156) 97 (67-125) <0.001
AFP, ng/mL 3.4 (2.1-6.4) 3.1 (2-5.8) 4.4 (2.7-8.4) <0.001
AST, IU/L 49 (34-75) 47 (33-73) 58 (34-75) <0.001
ALT, IU/L 37 (25-61) 35 (24-57) 45 (28-79) 0.001
Total bilirubin, mg/dL 1.0 (0.7-1.7) 1.0 (0.7-1.7) 1.1 (0.8-1.8) 0.03
Alkaline phosphatase, IU/L 116 (87-163) 115 (87-167) 117 (89-160) 1.0
Albumin, g/dL 3.8 (3.3-4.2) 3.8 (3.3-4.2) 3.7 (3.2-4.2) 0.36
INR 1.1 (1.0-1.3) 1.1 (1-1.2) 1.2 (1.1-1.3) 0.01
Imaging, median (IQR; range)
Total US 4 (2-7; 1-19) 4 (2-6; 1-19) 5 (3-7; 1-14) <0.001
Total CT/MRI 1 (0-2; 0-12) 0 (0-1; 0-12) 2 (1-3; 0-12) <0.001
Outcomes
HCC or empiric treatment for HCC 69 (6.9) 0 69 (27.0) <0.001
Hepatic decompensation 532 (53.3) 394 (53.0) 138 (53.9) 0.87
Variceal bleeding 112 (11.2) 87 (11.7) 25 (9.8)
Ascites 319 (31.9) 227 (30.6) 92 (35.9)
Hepatic encephalopathy 99 (9.9) 79 (10.6) 20 (7.8)
NOTE: Data are given as median (IQR) and n (%) unless otherwise noted.
*Includes 22 patients with cryptogenic cirrhosis.
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imaging appointment during follow-up, one-third 
(30%) missed 2, and 26% missed 3 or more imaging 
appointments.
In the overall cohort, the median number of US con-
ducted was 4 (IQR, 2-7; range, 1-19), and the median 
number of CT/MRIs was 1 (IQR, 0-2; range, 0-12). 
Among all imaging studies performed for HCC sur-
veillance or for clinical reasons other than follow-up of 
INs, 89.6% were conducted as an outpatient, 7.4% as 
an inpatient, and 2.9% in the emergency department. 
The indication for most imaging studies was primarily 
for HCC surveillance in 81.5%, diagnostic purposes in 
18%, and unspecified in 0.5%.
prOpOrtiOn OF patients WitH 
ins anD Hcc
A summary of surveillance results and follow-up 
evaluation is depicted in Fig. 1. A suspicious nodule 
was detected in 256 (26%) patients during US sur-
veillance over a median period of 2.2 years (IQR, 
0.9-3.9 years). The median number of nodules seen 
on US was 1 (IQR, 1-2), and the median size was 
1.7 cm (IQR, 1.2-2.5 cm). HCC was diagnosed in 
69 (6.9%) patients, of whom 78% were within Milan 
criteria or less. Specifically, 14 had T1 tumor burden; 
36 had T2; and 3 with advanced HCC (metastatic 
disease). Of these patients, 38 were diagnosed on 
initial CT/MRI after abnormal US, and 31 patients 
required multiple CT/MRIs (median, 2, IQR, 1-3; 
range, 1-12) after an abnormal US to make a diag-
nosis of HCC during a median follow-up time of 
0.7 years (IQR, 0.1-1.2 years) after IN was detected 
(Fig. 2A,B). A total of 10 patients had missed lesions 
with HCC diagnosed on initial CT/MRI in the set-
ting of a normal US. There was a median time of 18 
days (IQR, 3-163 days) from the normal US to HCC 
diagnosis in these 10 patients. In these patients, 
cross-sectional imaging was prompted by elevated 
AFP in 1 patient, poor US quality in 2 patients, rea-
sons other than surveillance in 2 patients, and unclear 
reasons in 5 patients. These patients had similar clin-
ical and demographic characteristics when compared 
with the remainder of the cohort with similar age 
(60.0 versus 58.0 years), BMI (29 versus 29 kg/m2), 
and similar liver function (all nonsignificant).
Among the 187 patients with an IN on US but 
without HCC during the study period, 18 (9.6%) 
had not undergone CT/MRI for diagnostic evalu-
ation after a median follow-up of 0.63 years (IQR, 
0-1.7). Of the 169 patients who had further evalua-
tion with CT/MRI, 132 (78.1%) were determined to 
Fig. 1. A summary of imaging findings and subsequent evaluation.
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be false-positive results and returned to surveillance 
US after a median of 2 CT/MRIs (IQR, 1-3; range, 
1-10) during a median follow-up of 1.9 years (IQR, 
1.1-3.2 years) after the IN was detected. Among 
these patients, 49.5% had 1 CT/MRI, 18.0% had 2, 
13.6% had 3, and 18.9% had ≥4 CT/MRIs after IN 
Fig. 2. CT/MRI utilization among patients with abnormal imaging (A) without and (B) with diagnosis of HCC.
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detection. The remaining 37 (21.9%) patients were 
still categorized as indeterminate and undergoing CT/
MRI imaging (median, 1; IQR, 1-2; range, 1-5) at the 
end of the study period after a median follow-up of 
0.3 years (IQR, 0.1-0.7 years) following IN detection 
on US. Among these patients, 62.2% had 1 CT/MRI, 
18.9% had 2, 10.8% had 3, and 8.1% had ≥4 CT/MRI 
after IN detection.
Percutaneous liver biopsy was performed in 11 
patients with IN, of whom 6 were diagnosed with 
HCC and 5 were benign. One patient, who had 
a benign lesion on biopsy, experienced a biopsy- 
related complication of abdominal pain, which required 
an emergency department visit without the need for 
a transfusion or hospitalization. Overall, 17.1% of 
patients with INs on US experienced severe harm with 
either ≥4 cross-sectional imaging tests or a liver biopsy 
with no diagnosis of HCC.
cHaracteristics assOciateD 
WitH in anD Hcc
Characteristics of patients with normal imaging 
compared with those with abnormal imaging (IN or 
HCC) are displayed in Table 1. Patients with abnor-
mal imaging were more commonly male, more likely 
to have HCV cirrhosis, had lower platelet count, and 
higher AFP, AST, ALT, total bilirubin, and INR. 
However, there was no difference in the presence of 
any hepatic decompensation, including ascites, hepatic 
taBle 2. characteristics of patients With abnormal imaging Without or With subsequent Hcc Diagnosis
Baseline Clinical Characteristics Abnormal Imaging Without HCC (n = 187) Abnormal Imaging With HCC (n = 69) P Value
Age, years 58.2 (52.2-65.9) 61.1 (55.4-64.6) 0.12
Sex, male 105 (56.1) 47 (68.1) 0.08
Race 0.74
White 162 (90.5) 57 (87.7)
Black 8 (4.4) 4 (6.1)
Asian 7 (3.9) 3 (4.6)
Hispanic/Latino 6 (3.2) 2 (2.9) 0.90
Etiology of liver disease 0.76
HCV 75 (40.1) 33 (47.8)
Alcoholic cirrhosis 23 (12.3) 9 (13.0)
NASH/NAFLD 33 (17.6) 8 (11.6)
PBC/PSC 10 (5.3) 3 (4.3)
HBV 14 (7.5) 4 (5.8)
Other 32 (17.1) 13 (18.8)
BMI, kg/m2 29 (25-35) 30 (25-32) 0.74
Follow-up duration, years 3.3 (1.9-4.2) 1.8 (1.1-2.9) <0.001
Baseline laboratory values
MELD 7 (6-10) 8 (6-11) 0.02
Platelet count, K/µL 103 (75-132) 77 (52-106) <0.001
AFP, ng/mL 4 (2.3-7.3) 6.0 (3.5-12.1) 0.003
AST, IU/L 55 (39-88) 61 (45-103) 0.07
ALT, IU/L 45 (27.5-80) 46 (32-77) 0.88
Total bilirubin, mg/dL 1 (0.7-1.65) 1.3 (0.9-2) 0.02
Alkaline phosphatase, IU/L 111.5 (88-151.5) 140 (95-174) 0.01
Albumin, g/dL 3.8 (3.4-4.25) 3.3 (3.1-3.9) <0.001
INR 1.1 (1.1-1.2) 1.2 (1.1-1.3) <0.001
Imaging/diagnostics, median (IQR; range)
Total US 5 (4-8; 1-14) 3 (2-5; 1-10) <0.001
Total CT/MRI 2 (1-3; 0-12) 1 (1-3; 1-9) 0.19
Number of nodules on US 1 (1-2) 1 (1-3) 0.36
Size of largest nodule on US, cm 1.4 (1.1-2.0) 2.3 (1.8-2.8) <0.001
NOTE: Data are given as median (IQR) and n (%) unless otherwise noted.
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encephalopathy, or variceal bleeding. Compared with 
those with IN, patients with HCC had significantly 
higher MELD scores, alkaline phosphatase, and AFP; 
lower platelet count and albumin; larger nodule size; 
and were more likely to have hepatic decompensation 
(Table 2).
In a multivariate analysis of the overall cohort, 
no factors were independently associated with IN. 
However, baseline platelet count approached sig-
nificance (Supporting Table 1). Thrombocytopenia 
(odds ratio [OR], 2.75; 95% confidence interval 
[CI], 1.37-5.53) and hypoalbuminemia (OR, 2.77; 
95% CI, 1.43-5.35) were independently associated 
with HCC diagnosis (Table 3). In a subgroup mul-
tivariate analysis among those patients with abnor-
mal imaging, thrombocytopenia (OR, 3.67; 95% CI, 
1.46-9.23) and hypoalbuminemia (OR, 4.07; 95% 
CI, 1.56-10.63) continued to be associated with 
HCC diagnosis. Larger nodule size on US (≥2 cm) 
was also associated with diagnosis of HCC (OR, 
8.63; 95% CI, 3.55-20.92; Table 3).
Discussion
Our study is one of the first to quantify the benefits 
and harm of a structured US-based HCC surveillance 
program in a large cohort of cirrhosis patients followed 
in an academic tertiary care center. The structured 
surveillance program was able to achieve consistent 
surveillance completion in nearly half of all patients 
over a 2.2-year median follow-up and detected over 
75% of HCC patients at an early stage. However, these 
benefits were accompanied by physical harm, includ-
ing nearly 20% of patients having an IN requiring ad-
ditional diagnostic evaluation.
Our study builds upon our prior results demon-
strating the benefits of a structured surveillance 
program.(23) Our program using electronic medical 
record reminders achieved consistent HCC surveil-
lance every 6 months in 46% of enrolled cirrhosis 
patients over a median of 2.2 years. Furthermore, 
most patients without consistent surveillance only 
missed 1 or 2 surveillance examinations. These 
results are notable because most prior studies in the 
United States reported consistent surveillance rates 
of only 5%-10% when assessed over extended study 
periods.(11) For example, a study investigating the 
effectiveness of a mailed outreach program dou-
bled 1-time HCC screening (47%) compared with 
usual care, but longitudinal surveillance was only 
5% over an 18-month period.(28) A review of hepa-
tology provider orders noted that nearly all (>95%) 
patients enrolled in the program had orders for 
HCC surveillance at 6-month intervals. Therefore, 
this structured program addresses provider oversight 
as a source of surveillance failure, which has been 
reported as the most common failure in the HCC 
screening process.(29) A potential contributing factor 
to suboptimal surveillance completion rates is that 
outside imaging reports may not have been accu-
rately captured. To circumvent this issue, we now try 
to schedule imaging the same day as patients’ clinic 
visits. Further research to optimize this multistep 
process and achieve higher rates of HCC surveillance 
completion is needed to improve early HCC detec-
tion. Increased HCC surveillance completion was 
associated with early HCC detection because over 
75% of HCC patients in our surveillance program 
were detected at an early stage. Ten patients were 
diagnosed in the setting of a normal US. However, 
the reasons for subsequent cross-sectional imaging 
varied, and we could not find any age or BMI differ-
ences to explain the false-negative US results.
The benefits of an HCC surveillance program 
must be weighed against observed HCC surveillance 
harm.(30) Over 15% of patients in our cohort had an 
IN that was determined to be benign or remains inde-
terminate and continues to undergo diagnostic evalua-
tion. Our results are similar to a study from a safety-net 
health system, in which 22.7% of cirrhosis patients 
taBle 3. multivariate analysis of predictors of 
Hcc Diagnosis
OR 95% CI P Value
Within overall cohort
Age, year 1.01 0.97-1.04 0.51
Sex, male 1.56 0.82-2.99 0.17
Baseline MELD 0.98 0.91-1.06 0.74
Baseline low platelets (<100 K/µL) 2.75 1.37-5.53 0.004
Baseline AFP 1.00 0.99-1.02 0.37
Baseline albumin (<3.4 g/dL) 2.77 1.43-5.35 0.002
Patients with abnormal imaging
Age, year 1.00 0.96-1.04 0.83
Sex, male 1.02 0.43-2.41 0.06
Baseline MELD 0.92 0.81-1.05 0.23
Baseline thrombocytopenia (<100 K/µL) 3.67 1.46-9.23 0.006
Baseline AFP 1.02 0.99-1.05 0.15
Baseline hypoalbuminemia (<3.4 g/dL) 4.07 1.56-10.63 0.004
Maximum nodule size (≥2.0 cm) 8.63 3.55-20.92 <0.001
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underwent “unnecessary” imaging due to indetermi-
nate or false-positive surveillance tests.(25) Most sur-
veillance-related “harm” in the study by Atiq et al.(25) 
was limited to a single CT or MRI diagnostic examina-
tion, although some patients experienced moderate to 
severe harm, defined as repeated cross-sectional imag-
ing or invasive evaluation with biopsy or angiogram. In 
our study, over half of patients with INs also underwent 
repeated cross-sectional imaging or invasive evaluation 
with biopsy. We were able to quantify the number of 
cross-sectional examinations in all patients with INs, 
adding further granularity to the data on harm related 
to HCC surveillance. However, notably, there were 31 
patients who required multiple cross-sectional imaging 
tests and 6 patients who required biopsy to diagnose 
HCC, highlighting the fact that it can be difficult to 
define what is “excessive” or “unnecessary” diagnostic 
evaluation at the time.
There is a clear need for better risk-stratification 
tools to differentiate HCC from benign lesions to 
reduce unnecessary imaging. Unfortunately, we did 
not identify any demographic or clinical factors cor-
related with IN. Thus, we failed to identify subgroups 
who may benefit from alternate modalities of surveil-
lance. However, other studies suggest US false-posi-
tive and indeterminate results may be more likely in 
obese patients, those with alcohol- or NASH-related 
cirrhosis, and those with more advanced liver dys-
function.(25,31,32) Controversy still surrounds the use 
of AFP in surveillance,(33) and although AFP levels 
were statistically significantly higher in those patients 
with HCC when compared with those patients with 
IN in our cohort, this difference was not clinically sig-
nificant. Accurate risk stratification for HCC devel-
opment remains a challenging task with most studies 
only able to achieve modest predictive accuracy.(34,35) A 
study of 494 hepatitis B virus (HBV)–infected patients 
with INs noted that age, nodule size, arterial enhance-
ment, albumin, and AFP levels were independently 
predictive of HCC progression. The associated predic-
tive model had an area under the curve of 0.88 and 0.92 
for 3- and 5-year risk prediction.(36) This model still 
requires external validation because it is unclear how 
the model would perform in heterogeneous patient 
populations with different etiologies of liver disease. 
In our study, we found thrombocytopenia and hypo-
albuminemia were independently predictive of HCC 
development among the overall cohort. In addition 
to these factors, nodule size was also associated with 
HCC in the subset of patients with abnormal imaging.
There are several notable limitations with our study. 
The study was performed at a single center, so it is 
unknown if our results can be generalized to other cen-
ters. However, our data are consistent with what has 
been reported in the literature.(25) As demonstrated in 
Table 1, our patient population is relatively homoge-
neous in terms of race and ethnicity, which has been 
associated with variable incidence rates of HCC. 
However, we did have diverse etiologies of chronic 
liver disease, which represents a strength over much 
of the existing literature that focuses on HCC risk 
within disease-specific groups (ie, HBV or HCV). 
Additionally, our center does not routinely perform 
contrast-enhanced US which could be included as 
part of a diagnostic algorithm for IN where available 
and could be effective in reducing the number of CT/
MRIs performed. Second, some patients with abnor-
mal imaging were still in the process of evaluation, 
and we may have overestimated the IN rate because 
some of these patients could have been diagnosed with 
HCC after the data collection had been completed. 
We mitigated this by excluding patients who had not 
yet received multiphasic cross-sectional imaging after 
IN detection in calculating the IN rate. Patients with 
nodules on cross-sectional imaging are at increased 
risk of eventually developing HCC. However, contin-
ued surveillance of nodules until they meet diagnostic 
criteria for HCC can be prolonged, incurring costs and 
causing patient anxiety. The optimal timing of when 
to return to US surveillance remains an open question. 
Third, given the study design, we did not capture the 
psychological harm of surveillance for HCC and the 
psychological burden of having an IN. Fourth, the 
study spanned the introduction of LI-RADS radio-
graphic criteria for HCC and nodule diagnosis on 
cross-sectional imaging, so the LI-RADS classification 
for the INs was not readily available for this analysis. 
Although the LI-RADS classification is an important 
tool in classifying nodules seen on dynamic imaging, 
it lacks thorough validation. Importantly, there is lit-
tle guidance on the management and follow-up for 
indeterminate (LI-RADS3 and LI-RADS4) lesions, 
especially ones that are identified on serial imaging.(37) 
Thus, we believe these data in INs are relevant even 
without LI-RADS classification of the INs. Lastly, as 
a retrospective analysis, there are inherent limitations 
in determining indications for imaging studies and the 
possibility of provider bias influencing which patients 
received cross-sectional imaging, whether liver tumor 
board review was conducted, and their follow-up.
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In conclusion, a structured HCC surveillance pro-
gram effectively promoted HCC surveillance com-
pletion and detected over 75% of HCC at an early 
stage. However, over 15% of patients in the surveil-
lance program had suspicious nodules prompting 
CT/MRI evaluation that did not lead to HCC diag-
nosis. This information is critically important when 
counseling patients on the risks and benefits upon 
entering an HCC surveillance program. Improved risk- 
stratification tools are needed to better predict HCC 
risk as well as better differentiate benign from malig-
nant nodules to maximize the value of HCC surveil-
lance in patients with cirrhosis.
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